Recruiting

Testing a new medication to protect kidneys in type 1 diabetes

Plain-English translation of NCT05822609 on ClinicalTrials.gov ↗ · Source last updated August 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether a medication called can help protect the kidneys of people with type 1 diabetes. The study will compare to a placebo (a dummy pill with no medicine) to see if the medication improves kidney health and blood sugar control. Researchers will use continuous glucose monitoring to carefully track your blood sugar throughout the study.

Type 1 diabetes can damage the kidneys over time, leading to serious health problems. Doctors want to know if this medication can slow or prevent that kidney damage by improving how much oxygen the kidneys receive and reducing harmful protein loss in the urine.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been living with type 1 diabetes for at least 5 years
you have had protein in your urine (shown by two recent tests) indicating early kidney damage
your kidney function is still reasonably good (measured by a glomerular filtration rate of at least 30)
you are on stable doses of blood pressure and cholesterol medications that you've been taking for at least 4 weeks

You likely don't qualify if…

you have had very high blood sugar (HbA1c over 9%) or recent serious diabetes complications like diabetic ketoacidosis
you have a family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2
you are currently taking other diabetes medications not approved for type 1 diabetes (such as metformin or SGLT2 inhibitors)
you are pregnant, breastfeeding, or planning to become pregnant
you have had more than 2 severe low blood sugar episodes in the past 6 months that required help from another person

What participation looks like

You will participate for 26 weeks (about 6 months). During the first part, you'll wear a continuous glucose monitor to help balance your blood sugar while taking study medication (or placebo). Over 12 weeks, your dose of medication will be gradually increased to the full amount. You'll then stay on that dose for the remaining weeks while researchers measure changes in your kidney health, blood sugar control, and insulin needs through blood and urine tests.

AI-generated summary from trial data · Jun 2, 2026 · Not medical advice

Trial locations(4 sites)

United States

University of Colorado Anschutz Medical Campus, Aurora, Colorado

University of Washington, Seattle, Washington

Providence Sacred Heart Medical Center, Spokane, Washington

Canada

Toronto General Hospital, University Health Network, Toronto, Ontario